Last reviewed · How we verify
CCP
CCP is a convalescent plasma product that provides passive immunotherapy through antibodies from recovered COVID-19 patients to treat active SARS-CoV-2 infection.
CCP is a convalescent plasma product that provides passive immunotherapy through antibodies from recovered COVID-19 patients to treat active SARS-CoV-2 infection. Used for COVID-19 (acute infection, particularly in hospitalized or immunocompromised patients).
At a glance
| Generic name | CCP |
|---|---|
| Also known as | convalescent plasma |
| Sponsor | Metro Infectious Disease Consultants |
| Drug class | Convalescent plasma |
| Target | SARS-CoV-2 spike protein and other viral antigens |
| Modality | Biologic |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Convalescent plasma contains polyclonal antibodies against SARS-CoV-2 that were generated in recovered patients. When transfused into acutely infected patients, these antibodies provide immediate passive immunity to neutralize circulating virus and enhance viral clearance. The mechanism relies on antibody-mediated viral neutralization and complement activation rather than stimulating the recipient's own immune response.
Approved indications
- COVID-19 (acute infection, particularly in hospitalized or immunocompromised patients)
Common side effects
- Transfusion-related acute lung injury (TRALI)
- Allergic reactions
- Volume overload
- Transfusion-transmitted infection
Key clinical trials
- Game Changers for Cervical Cancer Prevention (NA)
- Risk of Hydroceles Following Pyeloplasty
- Community Based Cannabis Cessation Program
- Pilot Study: Effects of CCP Intervention on NICU Environment and Preterm Infants Development (NA)
- Comprehensive Care Physician: Integrated Inpatient and Outpatient Care for Patients at High Risk of Hospitalization (NA)
- Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma
- Testing the Efficacy of the Cannabis Clinic for Patients With Psychosis (CCP) Intervention for Cannabis Use Reduction/Cessation in Patients With First Episode Psychosis (FEP) (NA)
- AOSEPT (CLEAR CARE) PLUS Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CCP CI brief — competitive landscape report
- CCP updates RSS · CI watch RSS
- Metro Infectious Disease Consultants portfolio CI